Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

Ip Tim Lau,1 Ka Fai Lee,2 Wing Yee So,3 Kathryn Tan,4 Vincent Tok Fai Yeung5 1Department of Medicine, Tseung Kwan O Hospital, 2Department of Medicine and Geriatrics, Kwong Wah Hospital, 3Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, 4Department o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lau IT, Lee KF, So WY, Tan K, Yeung VTF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Diabetes Mellitus Long-acting Insulin Insulin Glargine Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/7bf9792a91224c5ba421aa31716f6fc6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7bf9792a91224c5ba421aa31716f6fc6
record_format	dspace
spelling	oai:doaj.org-article:7bf9792a91224c5ba421aa31716f6fc62021-12-02T02:17:47ZInsulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus1178-7007https://doaj.org/article/7bf9792a91224c5ba421aa31716f6fc62017-06-01T00:00:00Zhttps://www.dovepress.com/insulin-glargine-300-uml-for-basal-insulin-therapy-in-type-1-and-type--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Ip Tim Lau,1 Ka Fai Lee,2 Wing Yee So,3 Kathryn Tan,4 Vincent Tok Fai Yeung5 1Department of Medicine, Tseung Kwan O Hospital, 2Department of Medicine and Geriatrics, Kwong Wah Hospital, 3Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, 4Department of Medicine, Queen Mary Hospital, University of Hong Kong, 5Department of Medicine and Geriatrics, Our Lady of Maryknoll Hospital, Hong Kong, China Objective: To review published clinical studies on the efficacy and safety of new insulin glargine 300 units/mL (Gla-300), a new long-acting insulin analog, for the treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM)Materials and methods: Data sources comprised primary research articles on Gla-300, including pharmacodynamic, pharmacokinetic, and clinical studies.Results: In pharmacodynamic and pharmacokinetic studies, Gla-300 showed a flatter time–action profile and longer duration of action than Gla-100. Noninferiority of Gla-300 versus Gla-100 for lowering of glycated hemoglobin was demonstrated in Phase III clinical studies covering a range of T1DM and T2DM patient populations. Over 6–12 months of follow-up, Gla-300 consistently showed comparable glycemic efficacy with less hypoglycemia vs Gla-100, even during the first 8 weeks of treatment. Although titrated insulin doses were 11%–17% higher with Gla-300 vs Gla-100, changes in body weight were similar or favored Gla-300.Conclusion: Clinical studies provide evidence that the pharmacodynamic and pharmacokinetic properties of Gla-300 may translate into clinical benefits in both T1DM and T2DM. Gla-300 may provide a new option for people initiating basal insulin, those requiring higher basal insulin doses, those with T1DM, and those who may be at increased risk for hypoglycemia, such as people with chronic kidney disease, the elderly, and those with cardiovascular comorbidities. Keywords: diabetes mellitus, long-acting insulin, insulin glargineLau ITLee KFSo WYTan KYeung VTFDove Medical PressarticleDiabetes MellitusLong-acting InsulinInsulin GlargineSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 273-284 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diabetes Mellitus Long-acting Insulin Insulin Glargine Specialties of internal medicine RC581-951
spellingShingle	Diabetes Mellitus Long-acting Insulin Insulin Glargine Specialties of internal medicine RC581-951 Lau IT Lee KF So WY Tan K Yeung VTF Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
description	Ip Tim Lau,1 Ka Fai Lee,2 Wing Yee So,3 Kathryn Tan,4 Vincent Tok Fai Yeung5 1Department of Medicine, Tseung Kwan O Hospital, 2Department of Medicine and Geriatrics, Kwong Wah Hospital, 3Department of Medicine and Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, 4Department of Medicine, Queen Mary Hospital, University of Hong Kong, 5Department of Medicine and Geriatrics, Our Lady of Maryknoll Hospital, Hong Kong, China Objective: To review published clinical studies on the efficacy and safety of new insulin glargine 300 units/mL (Gla-300), a new long-acting insulin analog, for the treatment of type 1 and type 2 diabetes mellitus (T1DM, T2DM)Materials and methods: Data sources comprised primary research articles on Gla-300, including pharmacodynamic, pharmacokinetic, and clinical studies.Results: In pharmacodynamic and pharmacokinetic studies, Gla-300 showed a flatter time–action profile and longer duration of action than Gla-100. Noninferiority of Gla-300 versus Gla-100 for lowering of glycated hemoglobin was demonstrated in Phase III clinical studies covering a range of T1DM and T2DM patient populations. Over 6–12 months of follow-up, Gla-300 consistently showed comparable glycemic efficacy with less hypoglycemia vs Gla-100, even during the first 8 weeks of treatment. Although titrated insulin doses were 11%–17% higher with Gla-300 vs Gla-100, changes in body weight were similar or favored Gla-300.Conclusion: Clinical studies provide evidence that the pharmacodynamic and pharmacokinetic properties of Gla-300 may translate into clinical benefits in both T1DM and T2DM. Gla-300 may provide a new option for people initiating basal insulin, those requiring higher basal insulin doses, those with T1DM, and those who may be at increased risk for hypoglycemia, such as people with chronic kidney disease, the elderly, and those with cardiovascular comorbidities. Keywords: diabetes mellitus, long-acting insulin, insulin glargine
format	article
author	Lau IT Lee KF So WY Tan K Yeung VTF
author_facet	Lau IT Lee KF So WY Tan K Yeung VTF
author_sort	Lau IT
title	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
title_short	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
title_full	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
title_fullStr	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
title_full_unstemmed	Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
title_sort	insulin glargine 300 u/ml for basal insulin therapy in type 1 and type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/7bf9792a91224c5ba421aa31716f6fc6
work_keys_str_mv	AT lauit insulinglargine300umlforbasalinsulintherapyintype1andtype2diabetesmellitus AT leekf insulinglargine300umlforbasalinsulintherapyintype1andtype2diabetesmellitus AT sowy insulinglargine300umlforbasalinsulintherapyintype1andtype2diabetesmellitus AT tank insulinglargine300umlforbasalinsulintherapyintype1andtype2diabetesmellitus AT yeungvtf insulinglargine300umlforbasalinsulintherapyintype1andtype2diabetesmellitus
_version_	1718402604572082176

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

Ejemplares similares